Please login to the form below
UK pricing agreement
This page shows the latest UK pricing agreement news and features for those working in and with pharma, biotech and healthcare.
AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
AbbVie and Eli Lilly have left the UK’s Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), according to an update by the Association of the British Pharmaceutical Industry (ABPI). ... huge potential of the life sciences sector to drive
Latest news
-
Europe responding to gene therapy challenge, but picture remains fragmented
This means the agreement needs to be based on clear and unambiguous clinical criteria, such as overall survival, or whether the treatment has prevented the need for the patient to have ... The new framework will build on the new UK-wide pricing agreement,
-
New ‘voluntary’ UK pricing deal caps growth, but promises faster uptake
Decades old PPRS name to go. The UK government and the pharmaceutical industry organisation the ABPI have unveiled a new 5 year pricing deal, called the ‘Voluntary scheme for branded medicines ... The government has tried to counterbalance the effects
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
The deal is done. After undoubtedly tense negotiations, the heads of terms for the new Voluntary Scheme for Branded Medicines Pricing and Access have just been published, and although some among ... By Leslie Galloway, chairman, Ethical Medicines
-
The UK’s new five-year pricing agreement
The UK has a new five-year Voluntary Pricing and Access Scheme (VPAS) for branded medicines, which came into force on 1 January 2019. ... Read the full 2019 Voluntary Scheme for Branded Medicines Pricing and Access document here.
-
Comment: the new UK pricing deal – welcome news, but lessons to be learned
Leslie Galloway, chairman of EMIG reflects on the new UK government-pharma industry pricing agreement. ... Leslie Galloway is chairman of the Ethical Medicines Industry Group EMIG, whose 270 member companies supply 50% of branded medicines by volume in
-
The NHS and ABPI at 70: inching closer to the triple win
Stevens said he believed there was still a need for an overarching UK pricing agreement, such as the PPRS, but NHS England’s role as the gatekeeper for new drugs - especially ... Nevertheless, Brexit does represent a huge risk for the life science
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
IPG Health Medical Communications
We are the world's most celebrated and awarded Medical Communications agencies. We are 800 experts obsessed with combining science, creativity...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
